natgillin/translations-raw huggingface dataset:
Den vigtigste målestok for virkningen var mændenes evne til at få og opretholde en erektion.
The main measure of effectiveness was based on the ability of the men to get and maintain an erection.
Resultaterne blev dokumenteret ved hjælp af et særligt spørgeskema, som deltagerne udfyldte hjemme, og hvori der blev anvendt en fempointsskala - med 5 som det bedste resultat.
This was recorded in a special questionnaire completed at home using a scoring system on a five-point scale, where a score of 5 represents the best result.
Viagra var væsentlig mere effektivt end placebo i alle undersøgelserne.
Viagra was significantly more effective than placebo in all studies.
I fastdosisundersøgelserne var den del af patienterne, som rapporterede, at behandlingen forbedrede deres erektioner 62% (25 mg), 74% (50 mg) og 82% (100 mg) sammenlignet med 25% på placebo.
In the fixed-dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25 mg), 74% (50 mg) and 82% (100 mg), compared with 25% on placebo.
Den hyppigste bivirkning ved Viagra (som optræder hos flere end 1 ud af 10 patienter) er hovedpine.
The most common side effect with Viagra (seen in more than 1 patient in 10) is headache.
Den fuldstændige liste over de indberettede bivirkninger ved Viagra fremgår af indlægssedlen.
For the full list of all side effects reported with Viagra, see the Package Leaflet.
Viagra må ikke anvendes til personer, som kan være overfølsomme (allergiske) over for sildenafil eller et af de øvrige indholdsstoffer, eller som er blevet frarådet seksuel aktivitet (f. eks. mænd med alvorlige hjertesygdomme såsom ustabile hjertekramper eller alvorlig hjerteinsufficiens).
Viagra should not be used in people who may be hypersensitive (allergic) to sildenafil or any of the other ingredients, or where sexual activity is inadvisable (e. g. men with severe heart disease such as unstable angina or severe heart failure).
Det må heller ikke indtages af patienter, som på noget tidspunkt har haft nedsat syn forårsaget af et problem med blodtilførslen til nerven i øjet (non- arteritis anterior iskæmisk opticusneuropati eller NAION).
It should also not be taken by patients who have ever had loss of vision because of a problem with blood flow to the nerve in the eye (non-arteritic anterior ischemic optic neuropathy or NAION).
Viagra må ikke indtages sammen med nitrater (lægemidler, der anvendes til behandling af hjertekrampe (angina)).
Viagra should not be taken with nitrates (medicines used to treat angina).
Viagra er ikke blevet undersøgt hos patienter med alvorlige leversygdomme, hypotension (for lavt blodtryk) eller patienter, som for nylig har haft et myokardieinfarkt (hjertetilfælde) eller et slagtilfælde, eller patienter med arvelige øjensygdomme som f. eks. retinitis pigmentosa (pigmentdegeneration af nethinden), og lægemidlet bør derfor ikke anvendes til disse patienter.
Because Viagra has not been studied in patients with severe liver disease, hypotension (low blood pressure), recent stroke or myocardial infarction (heart attack), or a hereditary eye disease, such as retinitis pigmentosa, these patients should not use it.
Hvorfor blev Viagra godkendt?
Why has Viagra been approved?
Udvalget for Humanmedicinske Lægemidler (CHMP) besluttede, at fordelene ved Viagra er større end risiciene ved behandling af mænd med erektil dysfunktion.
The Committee for Medicinal Products for Human Use (CHMP) decided that Viagra’ s benefits are greater than its risks for the treatment of men with erectile dysfunction.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Viagra.
The Committee recommended that Viagra be given marketing authorisation.
Andre oplysninger om Viagra:
Other information about Viagra:
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Viagra til Pfizer Limited den 14. september 1998.
The European Commission granted a marketing authorisation valid throughout the European Union for Viagra to Pfizer Limited on 14 September 1998.
Markedsføringstilladelsen blev fornyet den 14. september 2003 og den 14. september 2008.
The marketing authorisation was renewed on 14 September 2003 and on 14 September 2008.
Den fuldstændige EPAR for Viagra findes her.
The full EPAR for Viagra is available here.
EU- nummer EU/ 1/ 98/ 077/ 002 EU/ 1/ 98/ 077/ 003 EU/ 1/ 98/ 077/ 004 EU/ 1/ 98/ 077/ 006 EU/ 1/ 98/ 077/ 007 EU/ 1/ 98/ 077/ 008 EU/ 1/ 98/ 077/ 010 EU/ 1/ 98/ 077/ 011 EU/ 1/ 98/ 077/ 012 EU/ 1/ 98/ 077/ 013 EU/ 1/ 98/ 077/ 014 EU/ 1/ 98/ 077/ 015 EU/ 1/ 98/ 077/ 016
EU/ 1/ 98/ 077/ 002 EU/ 1/ 98/ 077/ 003 EU/ 1/ 98/ 077/ 004 EU/ 1/ 98/ 077/ 006 EU/ 1/ 98/ 077/ 007 EU/ 1/ 98/ 077/ 008 EU/ 1/ 98/ 077/ 010 EU/ 1/ 98/ 077/ 011 EU/ 1/ 98/ 077/ 012 EU/ 1/ 98/ 077/ 013 EU/ 1/ 98/ 077/ 014 EU/ 1/ 98/ 077/ 015 EU/ 1/ 98/ 077/ 016 EU/ 1/ 98/ 077/ 017 EU/ 1/ 98/ 077/ 018 EU/ 1/ 98/ 077/ 019
Særnavn VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA
VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA VIAGRA
Styrke 25 mg 25 mg 25 mg 50 mg 50 mg 50 mg 100 mg 100 mg 100 mg 25 mg 50 mg 100 mg 50 mg
25 mg 25 mg 25 mg 50 mg 50 mg 50 mg 100 mg 100 mg 100 mg 25 mg 50 mg 100 mg 50 mg 50 mg 50 mg 50 mg
Lægemiddelform Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter Filmovertrukne tabletter
Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet
Indgivelsesvej Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Emballage Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i karton Blister (PVC/ alu) i kortpakning
blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a carton blister (PVC/ alu) in a card blister (PVC/ alu) in a card blister (PVC/ alu) in a card blister (PVC/ alu) in a card
VIAGRA 25 mg filmovertrukne tabletter.
VIAGRA 25 mg film-coated tablets
Hver tablet indeholder 25 mg sildenafil som citrat.
Each tablet contains 25 mg of sildenafil(as citrate)
Hjælpestoffer: lactose.
Lactose
Blå, runde rhombeformede tabletter, mærket “ PFIZER ” på den ene side og "VGR 25 ” på den anden side.
Blue rounded diamond-shaped tablets, marked “ PFIZER ” on one side and “ VGR 25 ” on the other.
Behandling af mænd med erektil dysfunktion, hvilket er manglende evne til at opnå eller vedligeholde en erektion af penis, som er tilstrækkelig til tilfredsstillende seksuel aktivitet.
Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
Seksuel stimulation er nødvendig for at VIAGRA kan virke.
In order for VIAGRA to be effective, sexual stimulation is required.
Anvendelse hos voksne:
Use in adults:
På basis af effekt og tolerance kan dosis øges til 100 mg eller sænkes til 25 mg.
Based on efficacy and toleration, the dose may be increased to 100 mg or decreased to 25 mg.
5. 2).
If VIAGRA is taken with food, the onset of activity may be delayed compared to the fasted state (see section 5.2).
Anvendelse hos ældre:
Use in the elderly:
Dosisanbefalingerne under “ Anvendelse hos voksne ” gælder for patienter med let til moderat nedsat nyrefunktion (kreatininclearance = 30- 80 ml/ min.).
The dosing recommendations described in ‘ Use in adults ’ apply to patients with mild to moderate renal impairment (creatinine clearance = 30 - 80 ml/ min).
Da sildenafil clearance er nedsat hos patienter med alvorligt nedsat nyrefunktion (kreatininclearance < 30 ml/ min.) kan en 25 mg dosis overvejes.
Since sildenafil clearance is reduced in patients with severe renal impairment (creatinine clearance < 30 ml/ min) a 25 mg dose should be considered.
Vurderet ud fra effekt og tolerance kan dosis øges til 50 mg og 100 mg.
Based on efficacy and toleration, the dose may be increased to 50 mg and 100 mg.
Anvendelse hos patienter med nedsat leverfunktion:
2 Use in patients with impaired hepatic function:
Da sildenafil clearance er nedsat hos patienter med leverinsufficiens (f. eks. cirrhose) kan en 25 mg dosis overvejes.
Since sildenafil clearance is reduced in patients with hepatic impairment (e. g. cirrhosis) a 25 mg dose should be considered.
2 Anvendelse hos børn og unge:
Use in children and adolescents:
Anvendelse hos patienter, som får anden medicin:
Use in patients using other:
4. 5).
With the exception of ritonavir for which co-administration with sildenafil is not advised (see section 4.4) a starting dose of 25 mg should be considered in patients receiving concomitant treatment with CYP3A4 inhibitors (see section 4.5).
For at reducere muligheden for udvikling af postural hypotension bør patienter være stabile på alfa - blokkere, før sildenafilbehandling initieres.
In order to minimise the potential for developing postural hypotension, patients should be stable on alpha-blocker therapy prior to initiating sildenafil treatment.
4. 4 og 4. 5).
In addition, initiation of sildenafil at a dose of 25 mg should be considered (see sections 4.4 and 4.5).
5. 1) er det vist, at sildenafil potenserer nitraters hypotensive effekt, hvorfor indgift sammen med nitrogenoxiddonorer (som amylnitrit) eller enhver form for nitrater derfor er kontraindiceret.
Consistent with its known effects on the nitric oxide/ cyclic guanosine monophosphate (cGMP) pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated.
Stoffer til behandling af erektil dysfunktion, inklusive sildenafil, bør ikke anvendes af mænd, som frarådes seksuel aktivitet (f. eks. patienter med alvorlige kardiovæskulære lidelser som ustabil angina pectoris eller alvorligt hjertesvigt).
Agents for the treatment of erectile dysfunction, including sildenafil, should not be used in men for whom sexual activity is inadvisable (e. g. patients with severe cardiovascular disorders such as unstable angina or severe cardiac failure).
4. 4).
VIAGRA is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
Alvorlig leverinsufficiens, hypotension (blodtryk under 90/ 50 mmHg), nyligt overstået stroke eller hjerteinfarkt og kendte arvelige degenerative sygdomme i retina som retinitis pigmentosa (et mindretal af disse patienter har arvelige sygdomme i nethindens fosfodiesteraser).
The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: severe hepatic impairment, hypotension (blood pressure < 90/ 50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases).
5. 1).
Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1).
Patienter med øget følsomhed over for vasodilatorer omfatter patienter med obstruktion af venstresidig ventrikulær udløb (f. eks. aorta stenose, hypertrofisk obstruktiv kardiomyopati) eller patienter med det sjældne syndrom multipel systematrofi, som manifesterer sig som alvorligt nedsat autonom kontrol af blodtrykket.
Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (e. g., aortic stenosis, hypertrophic obstructive cardiomyopathy), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure.
4. 3).
VIAGRA potentiates the hypotensive effect of nitrates (see section 4.3).
Efter markedsføringen er der i forbindelse med brugen af VIAGRA rapporteret alvorlige kardiovaskulære hændelser, inklusiv myokardieinfarkt, ustabil angina pectoris, pludselig hjertedød, ventrikulær arytmi, cerebrovaskulær blødning, transitorisk cerebral iskæmi, hypertension og hypotension.
3 Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post-marketing in temporal association with the use of VIAGRA.
3 Præparater til behandling af erektil dysfunktion, inklusive sildenafil, bør anvendes med forsigtighed hos patienter med anatomisk deformitet af penis (som f. eks. vinkling, kavernøs fibrose eller Peyronie’ s sygdom), eller hos patienter med lidelser, som kan prædisponere til priapisme (som f. eks. seglcelleanæmi, multipelt myelom eller leukæmi).
Agents for the treatment of erectile dysfunction, including sildenafil, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’ s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).
Sikkerhed og effekt af kombinationer af sildenafil og andre behandlinger af erektil dysfunktion er ikke undersøgt.
The safety and efficacy of combinations of sildenafil with other treatments for erectile dysfunction have not been studied.
4. 3).
The patient should be advised that in case of sudden visual defect, he should stop taking VIAGRA and consult a physician immediately (see section 4.3).
4. 5).
Co-administration of sildenafil with ritonavir is not advised (see section 4.5).
4. 5).
Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the coadministration may lead to symptomatic hypotension in a few susceptible individuals (see section 4.5).
For at reducere muligheden for udvikling af postural hypotension bør patienter være hæmodynamisk stabile på alfa- blokker- behandling, før sildenafil- behandling initieres.
In order to minimise the potential for developing postural hypotension, patients should be hemodynamically stable on alpha- blocker therapy prior to initiating sildenafil treatment.
4. 2).
Initiation of sildenafil at a dose of 25 mg should be considered (see section 4.2).
VIAGRA tablettens filmovertræk indeholder lactose.
The film coating of the VIAGRA tablet contains lactose.
VIAGRA bør derfor ikke anvendes til mænd med arvelig galactoseintolerans, en særlig form af hereditær lactasemangel (Lapp Lactase deficiency) eller glucose/ galactosemalabsorption.
VIAGRA should not be administered to men with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
In vitro undersøgelser:
In vitro studies:
Derfor kan hæmmere af disse isoenzymer nedsætte clearance af sildenafil.
Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance.
Populationsfarmakokinetiske analyser af kliniske undersøgelsesdata tyder på en reduktion af sildenafils clearance ved indgift sammen med CYP3A4- hæmmere (som f. eks. ketoconazol, erythromycin, cimetidin).
Population pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, cimetidine).
Skønt der ikke ses en øget incidens af bivirkninger hos disse patienter, når sildenafil gives sammen med CYP3A4- hæmmere, bør en startdosis på 25 mg overvejes.
Although no increased incidence of adverse events was observed in these patients, when sildenafil is administered concomitantly with CYP3A4 inhibitors, a starting dose of 25 mg should be considered.
Samtidig indgift med HIV- proteasehæmmeren, ritonavir, som er en meget potent P450- hæmmer, ved steady state (500 mg 2 gange dagligt) og enkeltdosis af sildenafil (100 mg) gav en stigning i sildenafils Cmax på 300% (4 gange) og en stigning i sildenafils plasma AUC på 1. 000% (11 gange).
4 Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1,000% (11-fold) increase in sildenafil plasma AUC.
5 ng/ ml, når sildenafil bliver givet alene.
At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/ ml, compared to approximately 5 ng/ ml when sildenafil was administered alone.
4. 4) og den samlede dosis for sildenafil bør under ingen omstændigheder overstige 25 mg inden for 48 timer.
Based on these pharmacokinetic results co-administration of sildenafil with ritonavir is not advised (see section 4.4) and in any event the maximum dose of sildenafil should under no circumstances exceed 25 mg within 48 hours.
4 Samtidig indgift med HIV- proteasehæmmeren saquinavir, en CYP3A4- hæmmer, ved steady state (1200 mg 3 gange dagligt) og enkeltdosis sildenafil (100 mg) gav en stigning i sildenafils Cmax på 140% og en stigning i sildenafils plasma AUC på 210%.
Co-administration of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state (1200 mg three times a day) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.
Stærkere CYP3A4- hæmmere, som ketokonazol og itraconazol, forventes at have større effekt.
Stronger CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected to have greater effects.
Ved indgift af en enkeltdosis sildenafil 100 mg sammen med erythromycin, en specifik CYP3A4 - hæmmer, i steady state (500 mg 2 gange dagligt i 5 dage) sås en 182% stigning i optagelsen af sildenafil (AUC).
When a single 100 mg dose of sildenafil was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg twice daily. for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).
Hos raske frivillige forsøgspersoner gav cimetidin (800 mg), en cytokrom P450- hæmmer og ikke specifik CYP3A4- hæmmer en 56% stigning i plasmakoncentrationer af sildenafil ved indgift sammen med sildenafil (50 mg).
Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.
Enkeltdoser af antacida (magnesiumhydroxid/ aluminiumhydroxid) påvirkede ikke biotilgængelig - heden af sildenafil.
Single doses of antacid (magnesium hydroxide/ aluminium hydroxide) did not affect the bioavailability of sildenafil.
Skønt der ikke er foretaget specifikke interaktionsundersøgelser for alle lægemidler, viste populationsfarmakokinetiske analyser, at sildenafils farmakokinetik ikke blev påvirket ved samtidig indgift med CYP2C9 hæmmere (som tolbutamid, warfarin, fenytoin), CYP2D6 hæmmere (som selektive serotonin re- uptake hæmmere, tricykliske antidepressiva), tiazider og beslægtede diuretika, loop - og kaliumbesparende diuretika, ACE- hæmmere, calciumblokkere, beta- adrenerge receptorantagonister eller stoffer, som inducerer CYP450 metabolisme (som rifampicin, barbiturater).
Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant medication on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates).
På grund af nitratkomponenten har det potentiale for alvorlig interaktion med sildenafil.
Due to the nitrate component it has the potential to have serious interaction with sildenafil.
Sildenafil er en svag hæmmer af cytokrom P450- isoformer 1A2, 2C9, 2C19, 2D6, 2E1 og 3A4 (IC50 > 150 µM).
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 > 150 µM).
1 µM efter anbefalede doser, er det usandsynligt, at VIAGRA vil ændre clearance af substrater af disse isoenzymer.
Given sildenafil peak plasma concentrations of approximately 1 µM after recommended doses, it is unlikely that VIAGRA will alter the clearance of substrates of these isoenzymes.
Samtidig administration af sildenafil hos patienter, der er i alfa- blokker- behandling, kan hos få følsomme individer føre til symptomatisk hypotension.
5 Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to symptomatic hypotension in a few susceptible individuals.
I 3 specifikke lægemiddel - lægemiddel interaktionsundersøgelser blev alfa- blokkeren doxazosin (4 mg og 8 mg) og sildenafil (25 mg, 50 mg eller 100 mg) anvendt samtidigt hos patienter med benign prostatahyperplasi (BPH) stabiliseret på doxazosinbehandling.
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.
Hos disse studiepopulationer ses gennemsnitlig ekstra reduktioner i det systoliske og diastoliske blodtryk i liggende stilling på henholdsvis 7/ 7 mmHg, 9/ 5 mmHg og 8/ 4 mmHg, og gennemsnitlig ekstra reduktioner i blodtryk i stående stilling på henholdsvis 6/ 6 mmHg, 11/ 4 mmHg og 4/ 5 mmHg.
In these study populations, mean additional reductions of supine blood pressure of 7/ 7 mmHg, 9/ 5 mmHg, and 8/ 4 mmHg, and mean additional reductions of standing blood pressure of 6/ 6 mmHg, 11/ 4 mmHg, and 4/ 5 mmHg, respectively, were observed.
5 på doxazosinbehandling, ses af og til rapporter, hvor patienter oplever symptomatisk postural hypotension.
When sildenafil and doxazosin were administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension.
Sildenafil (50 mg) forstærker ikke den hypotensive effekt af alkohol hos raske frivillige forsøgspersoner med gennemsnitlig Cmax af alkohol i blodet på 80 mg/ dl.
Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80 mg/ dl.
Diuretika, beta- blokkere, ACE- hæmmere, angiotensin II antagonister, antihypertensiva (vasodilatatorer og centralt virkende), adrenerge neuroblokkere, calciumblokkere og alfa- adrenerge receptorblokkere viste ingen forskel i bivirkningsprofil hos patienter, som tog sildenafil sammenlignet med placebobehandling.
Pooling of the following classes of antihypertensive medication: diuretics, beta-blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products (vasodilator and centrally- acting), adrenergic neurone blockers, calcium channel blockers and alpha-adrenoceptor blockers, showed no difference in the side effect profile in patients taking sildenafil compared to placebo treatment.